Biden Administration’s Proposal to Retain 340B Hospital Drug Payment Cuts Draws More Fire

Groups whose members include 340B hospitals yesterday slammed CMS for proposing to continue deep drug payment cuts to 340B hospitals.

Several groups whose members include 340B hospitals yesterday slammed the Biden administration’s proposal to continue the Trump administration’s huge cut in Medicare Part B reimbursement for hospitals’ 340B purchased drugs.

The new administration yesterday announced its proposed plans for

Read More »

One-Fourth of 340B DSH Hospitals at Risk of Losing Eligibility Due to Pandemic, Analysis Finds

Many hospitals reduced inpatient admissions during the COVID-19 pandemic. 340B hospitals now fear that this could cause them to lose their eligibility for 340B drug discounts due to changes in patient mix.

Roughly one out of four 340B disproportionate share (DSH) hospitals could lose their eligibility for 340B drug discounts due to COVID-19 pandemic-related changes in patient mix, an analysis of hospital Medicare cost reports for 2019 and 2020 shows. About one

Read More »

Help Wanted Ads Suggest HRSA Reorganization Is in Gear

Recent HRSA job postings suggest that a reorganization announced in late January is finally in motion.

There are signs that the U.S. Health Resources and Services Administration (HRSA) reorganization announced in late January is finally in motion. It is still unknown, though, if the 340B program is moving to a new home in the HRSA administrator’s

Read More »

Providers Support, Eli Lilly Opposes, Rescinding Trump’s 340B Health Center Insulin Rule

Drug manufacturer Eli Lilly told HRSA is opposes rescinding a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

340B trade associations and covered entities submitted public comments overwhelmingly supporting the Biden administration’s proposal to rescind a Trump-era rule requiring community health centers to pass along savings on insulin and injectable epinephrine to low-income patients.

Drug manufacturer Eli Lilly,

Read More »

Breaking News

In Surprise Move, Biden Administration Proposes Keeping Trump’s Nearly 30% Cut in 340B Hospitals’ Drug Reimbursement

The U.S. Centers for Medicare & Medicaid Services (CMS) said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Biden administration said today it proposes to continue a nearly 30% reduction in Medicare Part B reimbursement for hospitals’ 340B-purchased drugs.

The Trump administration implemented the payment reduction in January 2018. Hospital groups say it costs affected 340B hospitals

Read More »

Biden Gives Becerra 45 Days to Deliver a Plan to Fight Excessive Drug Prices

President Biden has given HHS Secretary Xavier Becerra an Aug. 23 deadline for a plan “to combat excessive pricing of prescription drugs.”

President Biden last Friday gave U.S. Health and Human Services Secretary Xavier Becerra 45 days to deliver a plan “to combat excessive pricing of prescription drugs.” Becerra’s deadline is Aug. 23.

Biden included drug pricing directives in a far-ranging July

Read More »

HRSA Makes Tweaks to 340B Program Database

HRSA yesterday announced changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.

The U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) posted a notice yesterday about changes to the covered entity registration and manufacturer pricing components of 340B OPAIS, the 340B program database.

Today is the first day

Read More »

Three Drug Makers Answer HRSA’s 340B Contract Pharmacy Letters Defiantly

Lilly, Novartis, and Sanofi sent HRSA defiant responses to its May 17 letters telling the companies that their 340B contract pharmacy policies were illegal.

On May 17, the federal government told six drug companies that their 340B contract pharmacy policies were illegal, and it asked them to provide updates by June 1 on their plans to comply with the law.

At least three of

Read More »

CMS Taps Massachusetts Medicaid Director to Run Key Post Impacting 340B Program

Massachusetts Medicaid director Daniel Tsai has been named Director of CMS’s Center for Medicaid and CHIP Services.

The U.S. Centers for Medicare & Medicaid Services (CMS) announced on Monday that Massachusetts’ Medicaid director Daniel Tsai has been named Deputy Administrator of CMS and Director of CMS’s Center for Medicaid and CHIP Services (CMCS). A record 80 million

Read More »

NEWS ANALYSIS: Top Job at HRSA Remains Unfilled as Biden Presidency Enters its Sixth Month

HRSA recently held a webinar for hospitals ahead of their annual 340B recertification period.

Today is President Biden’s 155th day in office, and he has yet to pick someone to run the U.S. Health Resources and Services Administration (HRSA), the federal agency responsible for the 340B drug pricing program.

This normally might be a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live